2/2
08:00 am
vtvt
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
Medium
Report
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
1/27
08:04 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.
1/24
06:29 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
1/22
05:08 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
1/5
03:57 pm
vtvt
An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
Low
Report
An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
1/5
08:02 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.
1/5
07:03 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
12/30
04:16 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/27
01:05 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at
Wall Street Z
Low
Report
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at
Wall Street Z
12/24
07:01 pm
vtvt
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
12/23
04:14 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
vtvt
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
Low
Report
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
12/19
09:09 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/18
04:36 pm
vtvt
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
Low
Report
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
12/18
04:05 pm
vtvt
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Medium
Report
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
12/16
04:42 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/10
04:12 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
03:47 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:59 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
06:03 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
08:07 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.
11/18
01:23 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.